Nicotinic attenuation of CNS inflammation and autoimmunity
The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.
1. A method of treating a disease or condition in a subject, wherein the subject is a mouse, comprising:
providing a composition comprising a nicotinic receptor agent; and
administering a therapeutically effective dosage of the composition to the subject, wherein the therapeutically effective dosage of the nicotinic receptor agent ranges from 1 mg nicotine free base/kg to 60 mg nicotine free base/kg or wherein the therapeutically effective dosage of the nicotinic receptor agent is about 13 mg nicotine free base/kg/day administered over a period of 7 days.
2. The method of claim 1 , wherein the therapeutically effective dosage of the nicotinic receptor agent is about 13 mg nicotine free base/kg/day administered over a period of 7 days.
3. A method of treating a disease or condition in a subject, wherein the subject is a human, comprising:
providing a composition comprising and
administering a therapeutically effective dosage of the composition to the subject, wherein the therapeutically effective dosage of the nicotinic receptor agent ranges from nicotine plasma levels of 1 ng/mL to 100 ng/mL or wherein the therapeutically effective dosage of the nicotinic receptor agent is a nicotine plasma level of about 30 ng/mL.
4. The method of claim 3 , wherein the therapeutically effective dosage of the nicotinic receptor agent is a nicotine plasma level of about 30 ng/mL.
5. A method of treating a disease or condition in a subject, comprising:
providing a composition comprising a nicotinic receptor agent; and
administering a therapeutically effective dosage of the composition to the subject, wherein the disease or condition is multiple sclerosis (MS), acute disseminated encephalomyelitis, or experimental autoimmune encephalomyelitis (EAE).
6. The method of claim 5 , wherein the disease or condition is acute disseminated encephalomyelitis.
7. The method of claim 5 , wherein the disease or condition is experimental autoimmune encephalomyelitis (EAE).
8. The method of claim 5 , wherein the nicotinic receptor agent is administered to the subject continuously by an implanted pump.
9. A method of treating a disease or condition in a subject, comprising:
providing a composition comprising a nicotinic receptor agent; and
administering a therapeutically effective dosage of the composition to the subject, wherein the nicotinic receptor agent comprises nicotine bitartrate.
10. The method of claim 1 , wherein the therapeutically effective dosage of the nicotinic receptor agent ranges from 1 mg nicotine free base/kg to 60 mg nicotine free base/kg.
11. The method of claim 3 , wherein the therapeutically effective dosage of the nicotinic receptor agent ranges from nicotine plasma levels of 1 ng/mL to 100 ng/mL.
12. The method of claim 5 , wherein the disease or condition is multiple sclerosis (MS).